WHO Raises Concern Over Acute Scarcity of Weight-Loss Medications
Under a tenth of people that would benefit from obesity jabs including Wegovy can access them, states the global health agency as it releases its inaugural advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging increased and just availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 if no action is taken.
"Our latest guidance acknowledges that obesity is a chronic disease that can be managed with thorough and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and supply-chain constraints are key hurdles to broad availability to the injections that can aid individuals in losing substantial weight, says the organization.
Weight-Loss Drug Scarcity
Even in the current best projected outlook, the supply of such drugs could only cover approximately 100 million people – less than 10% of eligible patients, according to the WHO.
The recommendation calls on governments and firms to widen access, by measures like voluntary licensing.
The intellectual property rights on semaglutide – the main ingredient of the drug Wegovy – is set to lapse in several countries in 2026.
How Obesity Drugs Work
These medications replicate a biological compound to slow digestion, reduce hunger and enhance feelings of fullness so users reduce food intake.
Individuals typically start to lose weight in the initial weeks of commencing the regular doses.
Studies indicates people may see weight return after a year of stopping the medication, as their normal hunger return.
To be carrying excess weight raises your likelihood for experiencing diseases, including diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity impacts people in all nations and was associated with millions of fatalities worldwide in 2024, per the WHO.